Download full text in PDF

Suslova NI, Semionov OV. New approaches and prospects for the treatment of myxomatous degeneration of the mitral valve in dogs. Bìol Tvarin. 2025; 27 (4): 14–21. DOI: 10.15407/animbiol27.04.014.
https://doi.org/10.15407/animbiol27.04.014
Received 12.09.2025 ▪ Revision 14.01.2026 ▪ Accepted 18.01.2026 ▪ Published online 16.02.2026

New approaches and prospects for the treatment of myxomatous degeneration of the mitral valve in dogs

N. I. Suslova, O. V. Semionov
This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it.

Dnipro State Agrarian and Economic University, 25 Serhiya Yefremova str., Dnipro, 49009, Ukraine

Myxomatous mitral valve degeneration (MMVD) is the most common acquired heart disease in small and medium-sized dogs, leading to the development of chronic heart failure. The article summarizes current data (2020–2025) on new directions in the diagnosis, therapy and prevention of MVMD. Particular attention is paid to promising biomarkers (microRNA, SERPINH1, CILP1), innovative drugs (ARNI, SGLT2 inhibitors, antifibrotic agents), as well as approaches to individualizing treatment depending on breed, age and comorbidities. New technologies on cell and gene therapy, nanotechnology and minimally invasive surgical techniques (TEER) are separately highlighted.

Key words: myxomatous degeneration of the mitral valve, dogs, biomarkers, personalized therapy, ARNI, SGLT2 inhibitors, stem cells, gene therapy, TEER

1. Agarwal V, Kaple RK, Mehta HH, Singh P, Bapat VN. Current state of transcatheter mitral valve implantation in bioprosthetic mitral valve and in mitral ring as a treatment approach for failed mitral prosthesis. Ann Cardiothorac Surg. 2021; 10 (5): 585–604. DOI: 21037/acs-2021-tviv-80.
2. Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010; 24 (2): 331–341. DOI: 10.1111/j.1939-1676.2009.0467.x.
3. Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR., Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O’Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study — A randomized clinical trial. J Vet Intern Med. 2016; 30 (6): 1765–1779. DOI: 10.1111/jvim.14586.
4. Chanmongkolpanit K, Riengvirodkij N, Channgam P, Kaenchan P, Buayam W, Janhirun Y, Phonarknguen R, Tansakul M, Sakcamduang W. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?. Open Vet J. 2024; 14 (6): 1426–1441. DOI: 10.5455/OVJ.2024.v14.i6.10.
5. Chen J, Ren T, Xie L, Hu H, Li X, Maitusong M, Zhou X, Hu W, Xu D, Qian Y, Cheng S, Yu K, Wang J, Liu X. Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation. Nat Commun. 2024; 15 (1): 557. DOI: 10.1038/s41467-024-44726-0.
6. Fukuzumi S, Mandour AS, Farag A, Yoshida T, Nishiura A, Yotsuida H, Yaginuma Y, Matsuura K, Tanaka R. Speckle tracking echocardiography for evaluation of myocardial functions before and after mitral valvuloplasty in dogs. Front Vet Sci. 2024; 11: 1463889. DOI: 10.3389/fvets.2024.1463889.
7. Galizzi A, Dossi G, Pocar P, Borromeo V, Locatelli C. Plasma N-terminal pro-B-type natriuretic peptide and urinary aldosterone-to-creatinine ratio in healthy Chihuahuas. BMC Vet Res. 2024; 20 (1): 501. DOI: 10.1186/s12917-024-04344-w.
8. Giorgi ME, Mochel JP, Yuan L, Adin DB, Ward JL. Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left-sided congestive heart failure in dogs. J Vet Intern Med. 2022; 36 (6): 2042–2052. DOI: 10.1111/jvim.16571.
9. Hezzell MJ, Block CL, Laughlin DS, Oyama MA. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. J Vet Intern Med. 2018; 32 (5): 1509–1516. DOI: 10.1111/jvim.15228.
10. Hoda F, Negi H, Saini D, Arshad M, Zayed S, Raut MK, Habib MA, Akhtar M, Najmi AK. Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: Exploring efficacy and emerging concerns. Explor Med. 2024; 5: 774–796. DOI: 10.37349/emed.2024.00255.
11. Irqsusi M, Mansouri AL, Ramaswamy A, Rexin P, Salman M, Mahmood S, Mirow N, Ghazi T, Ramzan R, Rastan AJ, Vogt S. Role of matrix metalloproteinases in mitral valve regurgitation: Association between the of MMP-1, MMP-9, TIMP-1, and TIMP-2 expression, degree of mitral valve insufficiency, and pathologic etiology. J Card Surg. 2022; 37 (6): 1613–1622. DOI: 10.1111/jocs.16449.
12. Ishikawa N, Watanabe G. Robotic mitral valve repair in Japan and keyhole cardiac surgery in NewHeart Watanabe Institute. Ann Cardiothorac Surg. 2022; 11 (5): 538–539. DOI: 10.21037/acs-2022-rmvs-10.
13. Jeung S, An JH, Kim SS, Youn HY. Safety and efficacy of canine gonadal tissue-derived mesenchymal stem cells for early myxomatous mitral valve disease. Front Vet Sci. 2024; 11: 1404607. DOI: 10.3389/fvets.2024.1404607.
14. Katz MG, Ohad DG, Putter P, Shtraizent N, Shahar E, Tal S, Eliyahu E. Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease. Front Vet Sci. 2024; 11: 1415030. DOI: 10.3389/fvets.2024.1415030.
15. Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019; 33 (3): 1127–1140. DOI: 10.1111/jvim.15488.
16. Kim HJ, Kim J, Kim S, Kim HJ. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not? BMC Vet Res. 2023; 19 (1): 59. DOI: 10.1186/s12917-023-03583-7.
17. Kim J, Yoo JS. Totally endoscopic mitral valve repair using a three-dimensional endoscope system: Initial clinical experience in Korea. J Thorac Dis. 2020; 12 (3): 705–711. DOI: 10.21037/jtd.2019.12.126.
18. Kim TS, Hong CY, Oh SJ, Choe YH, Hwang TS, Kim J, Lee SL, Yoon H, Bok EY, Cho AR, Do YJ, Kim E. RNA sequencing provides novel insights into the pathogenesis of naturally occurring myxomatous mitral valve disease stage B1 in beagle dogs. PLoS One. 2024; 19 (5): e0300813. DOI: 10.1371/journal.pone.0300813.
19. Klein S, Nolte I, Granados-Soler JL, Lietz P, Sehn M, Raue JF, Rohn K, Packeiser EM, Bach JP. Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease. BMC Vet Res. 2022; 18 (1): 256. DOI: 10.1186/s12917-022-03343-z.
20. Lee GW, Kang MH, Ro WB, Song DW, Park HM. Circulating galectin-3 evaluation in dogs with cardiac and non-cardiac diseases. Front Vet Sci. 2021; 8: 741210. DOI: 10.3389/fvets.2021.741210.
21. Lee JM, Youp KA, Lee ST, Lee AR, Cho YW, Jung YS, Her J, Lee SK. Retrospective evaluation of transcatheter edge-to-edge mitral valve repair in dogs with myxomatous mitral valve disease. J Vet Intern Med. 2025; 39 (4): e70156. DOI: 10.1111/jvim.70156.
22. Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA. Metabolomics analysis reveals deranged energy metabolism and amino acid metabolic reprogramming in dogs with myxomatous mitral valve disease. J Am Heart Assoc. 2021; 10 (9): DOI: 10.1161/JAHA.120.018923.
23. Ljungvall I, Rajamäki MM, Crosara S, Olsen LH, Kvart C, Borgarelli M, Höglund K, Häggström J. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease. Am J Vet Res. 2011; 72 (8): 1022–1028. DOI: 10.2460/ajvr.72.8.1022.
24. McNair AJ, Markby GR, Tang Q, MacRae VE, Corcoran BM. TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease. Front Vet Sci. 2023; 10: 1202001. DOI: 10.3389/fvets.2023.1202001.
25. Mead SE, Beijerink NJ, O’Brien M, Wade CM. Genetic variants at the nebulette locus are associated with myxomatous mitral valve disease severity in Cavalier King Charles Spaniels. Genes. 2022; 13 (12): 2292. DOI: 10.3390/genes13122292.
26. Mitchell CL. The potential role of microRNA as bio markers in canine congestive heart failure. FASEB J. 2022; 36 (S1): R5230. DOI: 10.1096/fasebj.2022.36.S1.R5230.
27. Moesgaard SG, Aupperle H, Rajamäki MM, Falk T, Rasmussen CE, Zois NE, Olsen LH. Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor-β (TGF-β) in advanced canine myxomatous mitral valve disease. Res Vet Sci. 2014; 97 (3): 560–567. DOI: 10.1016/j.rvsc.2014.10.003.
28. Newhard DK, Jung S, Winter RL, Duran SH. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. J Vet Intern Med. 2018; 32 (5): 1555–1563. DOI: 10.1111/jvim.15240.
29. Noordin N, Khor KH, Lau SF, Ramanoon SZ, Ee KL. Associated risk factors, staging, and median survival time of dogs with degenerative mitral valve disease. Acta Vet Eurasia. 2023; 49 (2): 82–91. DOI: 10.5152/actavet.2022.0105.
30. Oyama MA, Elliott C, Loughran KA, Kossar AP, Castillero E, Levy RJ, Ferrari G. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms. Cardiovasc Pathol. 2020; 46: 107196. DOI: 10.1016/j.carpath.2019.107196.
31. Oyama MA, Scansen BA, Boswood A, Goldfeder G, Rosenthal S, Cober R, LaFauci K, Friese RC, Gomes M, Chang YMR, Li Q. Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease. J Vet Intern Med. 2023; 37 (4): 1323–1330. DOI: 10.1111/jvim.16796.
32. Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med. 2004; 18 (6): 831–839. DOI: 10.1892/0891-6640(2004)18%3C831:ctcidw%3E2.0.co;2.
33. Palarea-Albaladejo J, Bode EF, Partington C, Basili M, Mederska E, Hodgkiss-Geere H, Capewell P, Chauché C, Coultous RM, Hanks E, Dukes-McEwan J. Assessing the use of blood microRNA expression patterns for predictive diagnosis of myxomatous mitral valve disease in dogs. Front Vet Sci. 2024; 11: 1443847. DOI: 10.3389/fvets.2024.1443847.
34. Petchdee S, Pongkan W, Lei J, Jaturanratsamee K, Bootcha R, Meepoo W, Panprom C. Transcatheter edge-to-edge repair of the mitral valve in four dogs: Preliminary results regarding efficacy and Animals. 2024; 14 (21): 3068. DOI: 10.3390/ani14213068.
35. Potter BM, Orton EC, Scansen BA, Abbott-Johnson KM, Visser LC, Chi IJB, Ross ES, Del Nero B, Tantisuwat L, Krause ET, Rezende ML, Mama K. Clinical feasibility study of transcatheter edge-to-edge mitral valve repair in dogs with the canine V-Clamp device. Front Vet Sci. 2024; 11: 1448828. DOI: 10.3389/fvets.2024.1448828.
36. Rymskyi VV, Nedzvetsky VS. The effect of humic substances on the functional state of internal organs and antioxidant status in dogs with myxomatous mitral valve disease. Ukr J Vet Agr Sci. 2024; 7 (3): 42–47. DOI: 10.32718/ujvas7-3.07.
37. Saengklub N, Pirintr P, Nampimoon T, Kijtawornrat A, Chaiyabutr N. Short-term effects of sacubitril/valsartan on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease. Front Vet Sci. 2021; 8: 700230. DOI: 10.3389/fvets.2021.700230.
38. Svensson M, Selling J, Dirven M. Myxomatous mitral valve disease in large breed dogs: Survival characteristics and prognostic variables. Vet Sci. 2024; 11 (3): 136. DOI: 10.3390/vetsci11030136.
39. Syed SH, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, Abbas A, Said S, Mukherjee D. A Review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015; 13 (2): 105–112. DOI: 10.2174/1871525714666151106121215.
40. Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014; 44 (3): 303–308. DOI: 10.1111/eci.12234.
41. Tang Q, McNair AJ, Phadwal K, Macrae VE, Corcoran BM. The role of transforming growth factor-β signaling in myxomatous mitral valve degeneration. Front Cardiovasc Med. 2022; 9: 872288. DOI: 10.3389/fcvm.2022.872288.
42. Toaldo MB. Diagnosis and management of a more advanced stage of preclinical myxomatous mitral valve disease in dogs without echocardiography. Schweiz Archiv Tierheilkunde. 2024; 166 (12): 619–631. DOI: 17236/sat00438.
43. Tomsič K, Domanjko Petrič A, Nemec A, Pirman T, Rezar V, Seliškar A, Vovk T, Nemec Svete A. Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1. Front Vet Sci. 2023; 10: 1203480. DOI: 10.3389/fvets.2023.1203480.
44. Umezawa M, Fujii Y, Orito K, Yoshimoto R. Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the “right drug” and the “right dose” for dogs. J Vet Med Sci. 2025; 87 (6): 647–666. DOI: 10.1292/jvms.25-0040.
45. Van Staveren MDB, Muis E, Szatmári V. Self-reported utilization of International (ACVIM Consensus) guidelines and the latest clinical trial results on the treatment of dogs with various stages of myxomatous mitral valve degeneration: A survey among veterinary practitioners. Animals. 2024; 14 (5): 772. DOI: 10.3390/ani14050772.
46. Vilskersts R, Kigitovica D, Korzh S, Videja M, Vilks K, Cirule H, Skride A, Makrecka-Kuka M, Liepinsh E, Dambrova M. Protective effects of meldonium in experimental models of cardiovascular complications with a potential application in COVID-19. Int J Mol Sci. 2021; 23 (1): 45. DOI: 10.3390/ijms23010045.
47. Virgen-Ortiz A, Limón-Miranda S, Salazar-Enríquez DG, Melnikov V, Sánchez-Pastor EA, Castro-Rodríguez EM. Matrix metalloproteinases system and types of fibrosis in rat heart during late pregnancy and postpartum. Medicina. 2019; 55 (5): 199. DOI: 10.3390/medicina55050199.
48. Wilson BA, Wesselowski S. Myxomatous mitral valve disease in Labrador Retrievers and Golden Retrievers. J Am Vet Med Assoc. 2024; 262 (11): 1467–1475. DOI: 10.2460/javma.24.05.0303.
49. Yu J, Qiao E, Wang W. Mechanical or biologic prostheses for mitral valve replacement: A systematic review and meta-analysis. Clin Cardiol. 2022; 45 (7): 701–716. DOI: 10.1002/clc.23854.
50. Yu QG, Zhang Y. Transforming growth factor-β1 mediates NADPH oxidase 4: A significant contributor to the pathogenesis of myocardial fibrosis. Int J Cardiol. 2017; 227: 53–54. DOI: 10.1016/j.ijcard.2016.10.118.
51. Zhou Q, Cui X, Zhou H, Guo S, Wu Z, Li L, Zhang J, Feng W, Guo Y, Ma X, Chen Y, Qiu C, Xu M, Deng G. Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease. BMC Vet Res. 2023; 19 (1): 271. DOI: 10.1186/s12917-023-03789-9.
52. Zhou Q, Wu Z, Li L, Zhou H, Chen Y, Guo S, Guo Y, Ma X, Zhang J, Feng W, Cui X, Qiu C, Xu M, Deng G. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2. J Proteomics. 2023; 282: DOI: 10.1016/j.jprot.2023.104924.